NCT06365216 - ALS Phase II Study of NX210c | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

NX210c

3 times a week, for 4 weeks

DRUG

Placebo

3 times a week, for 4 weeks

Trial Locations (12)

33000

NOT_YET_RECRUITING

Centre Hospitalier Universitaire De Bordeaux, Bordeaux

34295

RECRUITING

Centre Hospitalier Universitaire de Montpellier, Montpellier

35000

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Rennes, Rennes

37044

NOT_YET_RECRUITING

Centre Hospitalier Regional Universitaire de Tours, Tours

44093

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Nantes - Hôpital Nord Laennec, Nantes

49100

RECRUITING

Centre Hospitalier Universitaire d'Angers, Angers

59037

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Lille, Lille

63003

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, Clermont-Ferrand

69500

RECRUITING

CHU de Lyon HCL, Bron

75013

RECRUITING

Hôpital de la Pitié Salpêtrière, Paris

87042

NOT_YET_RECRUITING

Centre Hospitalier Et Universitaire de Limoges, Limoges

06000

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Nice, Nice